AllAnalyst Report
logoMorningstarMarch 28, 2024

DaVita Inc.: Obesity Drug's Effects on Dialysis Likely To Be Less Than Feared

Symbols
DVA
Sector(s)
Healthcare
Rating
Current Price
$133.51
Fair Value
Economic Moat
Stewardship
Summary

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

Julie Utterback

Senior Analyst
Julie Utterback is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers life sciences firms in the healthcare industry.Utterback initially joined Morningstar in 2005 as an equity analyst in the healthcare industry. At that time, she covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage on the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until rejoining the equity team in April 2019.Prior to joining Morningstar, Utterback was an equity analyst at State Farm Insurance for several years. She holds a bachelor's degree in finance from the University of Illinois Urbana- Champaign. She also holds the Chartered Financial Analyst® designation.